+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Opioid Induced Constipation Market by Product Type, Oral, Rectal - Global Forecast to 2030- Product Image
Opioid Induced Constipation Market by Product Type, Oral, Rectal - Global Forecast to 2030- Product Image
Sale

Opioid Induced Constipation Market by Product Type, Oral, Rectal - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715749
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Opioid Induced Constipation Market grew from USD 70.10 million in 2024 to USD 75.03 million in 2025. It is expected to continue growing at a CAGR of 6.77%, reaching USD 103.86 million by 2030.

Navigating the Complexities of Opioid-Induced Constipation

Opioid-induced constipation poses a significant challenge across healthcare systems, affecting patient quality of life and complicating pain management protocols. As opioid therapies continue to play a critical role in addressing chronic and acute pain, the gastrointestinal side effects associated with mu-opioid receptor activation demand targeted solutions. Patients frequently endure discomfort, reduced medication adherence, and increased healthcare resource utilization due to constipation resistant to conventional laxatives. These clinical and economic burdens underscore an urgent need for innovative therapeutic approaches and data-driven decision making.

This executive summary synthesizes the current landscape, transformative shifts, and strategic imperatives shaping opioid-induced constipation treatment. It aims to equip industry leaders and decision-makers with a concise yet thorough analysis of market developments, segmentation dynamics, regulatory influences, and competitive forces. Through a structured exploration of tariffs, regional trends, product categories, and company strategies, readers will gain actionable insights to navigate evolving market conditions and improve patient outcomes.

Evolving Dynamics in Opioid-Induced Constipation Management

The landscape of opioid-induced constipation management is undergoing a profound transformation driven by regulatory scrutiny, evolving clinical guidelines, and heightened patient expectations. Payers and providers are increasingly emphasizing real-world outcomes and cost-effectiveness, compelling manufacturers to substantiate both safety and economic value. Novel digital health platforms now enable remote monitoring of bowel function and tailored adherence support, enhancing patient engagement and optimizing therapeutic regimens.

Simultaneously, the pipeline of peripherally acting mu-opioid receptor antagonists has expanded, offering targeted mechanisms that preserve analgesia while relieving gastrointestinal symptoms. Combination therapies integrating pelvic floor interventions are gaining traction, reflecting a holistic approach to motility disorders. These shifts, alongside growing interest in osmotic and stimulant laxatives with improved tolerability profiles, highlight the sector’s momentum toward patient-centric, evidence-based solutions. As stakeholders align on shared goals, collaboration between clinical, regulatory, and commercial functions becomes paramount to harness these transformative trends.

Assessing the Ripple Effects of 2025 U.S. Tariffs on the Sector

The introduction of United States tariffs in 2025 has reverberated across the opioid-induced constipation market, altering cost structures and strategic planning for manufacturers and distributors alike. Heightened duties on active pharmaceutical ingredients and excipients have driven input costs upward, prompting companies to reassess pricing strategies and supply chain footprints. To mitigate margin pressures, some stakeholders have diversified sourcing from alternative geographies or renegotiated long-term agreements with key suppliers.

Beyond direct cost implications, the tariff regime has influenced market access considerations. Payers are scrutinizing unit price increases, demanding robust pharmacoeconomic evidence to support reimbursement. Parallel trade dynamics have intensified as distributors seek arbitrage opportunities across regions with differential tariff applications. Consequently, manufacturers are deploying dynamic pricing frameworks and pursuing value-based contracting to balance commercial viability with patient affordability. These adaptive responses underscore the need for agile strategic planning in an environment shaped by evolving trade policies and fiscal constraints.

Unveiling Segmentation Patterns Driving Therapeutic Strategies

Insight into market segmentation reveals distinct therapeutic pathways and delivery formats shaping treatment adoption. Product categorization delineates a spectrum that spans combination therapies incorporating pelvic floor modalities, traditional laxatives subdivided into osmotic agents, stimulant compounds, and stool softeners, and peripherally acting mu-opioid receptor antagonists represented by alvimopan, methylnaltrexone, naldemedine, and naloxegol. Each category exhibits unique efficacy profiles, side-effect considerations, and commercialization strategies, informing tailored positioning across payer and provider channels.

Route of administration further refines treatment selection, as oral formulations encompass both liquid presentations such as solutions and suspensions, and solid dosage forms including capsules and tablets. These options cater to patient preferences, ease of use, and compliance factors. Meanwhile, rectal delivery via enemas and suppositories offers rapid onset for acute constipation episodes and serves as a vital adjunct for patients with impaired oral intake. The interplay between product type and administration route drives nuanced market dynamics, highlighting opportunities for differentiated value propositions and targeted marketing initiatives.

Regional Landscapes Shaping Treatment Accessibility and Adoption

Regional nuances critically influence market development, reflecting regulatory frameworks, reimbursement landscapes, and patient access considerations across geographies. In the Americas, robust reimbursement mechanisms and centralized formularies facilitate broad adoption of advanced antagonists, though pricing pressures prompt outcome-based agreements to balance cost and clinical benefit. Stakeholders leverage established distribution networks to introduce novel agents while refining patient support services to sustain adherence.

Across Europe, the Middle East and Africa, a mosaic of regulatory bodies and payer structures yields variable market entry timelines and pricing corridors. Countries with health technology assessment mandates prioritize real-world effectiveness, compelling localized evidence generation. Emerging markets in sub-Saharan Africa are characterized by constrained healthcare budgets and infrastructure challenges, underscoring the need for cost-effective, easily administered laxatives.

In the Asia-Pacific region, rapid healthcare modernization and rising patient awareness underpin growth opportunities. Reimbursement expansion in key markets enables broader access to premium therapies, while digital health integration accelerates telemedicine-enabled constipation management. Collaborative efforts with local partners streamline regulatory approvals and market penetration, reflecting the strategic importance of region-specific engagement models.

Competitive Landscape Spotlight on Leading Industry Players

The competitive landscape features a blend of established pharmaceutical companies and emerging specialty players vying for market leadership. Large multinationals leverage global manufacturing capabilities and extensive commercial footprints to launch peripherally acting mu-opioid receptor antagonists, supported by comprehensive patient education and reimbursement facilitation programs. Meanwhile, niche innovators drive differentiated product profiles through novel delivery systems and targeted indications, seeking partnerships to amplify reach.

Strategic alliances and licensing agreements have proliferated as companies aim to bolster pipelines and penetrate underserved segments. Collaboration between specialty manufacturers and contract research organizations accelerates development timelines and mitigates clinical risk. Additionally, mergers and acquisitions are reshaping the terrain, with key transactions focused on bolstering portfolios in the laxative category and expanding geographic coverage. This dynamic environment underscores the imperative for continuous intelligence gathering and competitive benchmarking to anticipate threats and capitalize on white-space opportunities.

Strategic Imperatives for Stakeholders to Drive Value and Growth

Industry leaders must adopt proactive strategies to capitalize on emerging trends and safeguard market share. Prioritizing investment in targeted antagonists with strong safety profiles can differentiate offerings and meet payer demand for value-based outcomes. Developing integrated patient support programs that leverage digital platforms will enhance adherence and demonstrate real-world effectiveness. Companies should also diversify supply chains to buffer against tariff-induced cost volatility and explore strategic partnerships that unlock regional expertise and distribution channels.

Moreover, robust engagement with regulatory bodies and health technology assessment agencies early in development can streamline market access pathways. Stakeholders should harness real-world evidence and pharmacoeconomic modeling to substantiate product value and facilitate outcome-based contracting. By aligning cross-functional teams around patient-centric objectives and leveraging agile commercial frameworks, organizations can navigate evolving trade policies and competitive pressures while driving sustainable growth.

Robust Research Framework Ensuring Analytical Rigor

This analysis is underpinned by a comprehensive research framework integrating primary and secondary data sources. In-depth interviews with key opinion leaders, clinical specialists, and payers furnished qualitative insights on evolving treatment paradigms and reimbursement trends. Secondary research encompassed peer-reviewed literature, regulatory filings, industry white papers, and proprietary trade databases to map market dynamics and tariff impacts.

Quantitative methodologies included segmentation analysis by product type, administration route, and region, with data triangulation ensuring accuracy and consistency. Rigorous validation protocols involved cross-checking findings against multiple sources and subjecting assumptions to reviewer scrutiny. Statistical techniques were applied to identify correlation patterns and support segmentation insights. This robust approach ensures that conclusions and recommendations rest on an objective, evidence-based foundation.

Synthesis of Insights and Forward-Looking Perspectives

The opioid-induced constipation landscape is at a pivotal juncture, shaped by evolving clinical standards, trade policies, and competitive maneuvers. Segmentation analysis highlights diverse therapeutic pathways, from combination pelvic floor approaches to advanced antagonists and patient-friendly formulations. Regional insights reveal distinct adoption drivers and access barriers, while tariff shifts necessitate agile pricing and supply chain strategies. Against this backdrop, leading companies are forging collaborations, optimizing pipelines, and leveraging real-world evidence to secure competitive advantage.

Moving forward, stakeholders that integrate patient-centric innovation with data-driven market intelligence will be best positioned to address unmet needs and create sustainable value. The strategic imperatives outlined herein offer a blueprint for navigating complexity, delivering differentiated solutions, and fostering collaborative ecosystems. By embracing these insights, decision-makers can chart a clear course through a dynamic therapeutic environment and ultimately improve outcomes for patients experiencing opioid-induced constipation.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Combination Therapies
      • Pelvic Floor Therapies
    • Laxatives
      • Osmotic Laxatives
      • Stimulant Laxatives
      • Stool Softeners
    • Peripherally Acting Mu-Opioid Receptor Antagonists
      • Alvimopan
      • Methylnaltrexone
      • Naldemedine
      • Naloxegol
  • Oral
    • Liquid
      • Solutions
      • Suspensions
    • Solid
      • Capsules
      • Tablets
  • Rectal
    • Enemas
    • Suppositories
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AstraZeneca plc
  • Shionogi & Co., Ltd.
  • H. Lundbeck A/S
  • Bausch Health Companies Inc.
  • Mundipharma International Limited
  • Merck & Co., Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Opioid Induced Constipation Market, by Product Type
8.1. Introduction
8.2. Combination Therapies
8.2.1. Pelvic Floor Therapies
8.3. Laxatives
8.3.1. Osmotic Laxatives
8.3.2. Stimulant Laxatives
8.3.3. Stool Softeners
8.4. Peripherally Acting Mu-Opioid Receptor Antagonists
8.4.1. Alvimopan
8.4.2. Methylnaltrexone
8.4.3. Naldemedine
8.4.4. Naloxegol
9. Opioid Induced Constipation Market, by Oral
9.1. Introduction
9.2. Liquid
9.2.1. Solutions
9.2.2. Suspensions
9.3. Solid
9.3.1. Capsules
9.3.2. Tablets
10. Opioid Induced Constipation Market, by Rectal
10.1. Introduction
10.2. Enemas
10.3. Suppositories
11. Americas Opioid Induced Constipation Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Opioid Induced Constipation Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Opioid Induced Constipation Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. AstraZeneca plc
14.3.2. Shionogi & Co., Ltd.
14.3.3. H. Lundbeck a/S
14.3.4. Bausch Health Companies Inc.
14.3.5. Mundipharma International Limited
14.3.6. Merck & Co., Inc.
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. OPIOID INDUCED CONSTIPATION MARKET MULTI-CURRENCY
FIGURE 2. OPIOID INDUCED CONSTIPATION MARKET MULTI-LANGUAGE
FIGURE 3. OPIOID INDUCED CONSTIPATION MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. OPIOID INDUCED CONSTIPATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. OPIOID INDUCED CONSTIPATION MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. OPIOID INDUCED CONSTIPATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PELVIC FLOOR THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STIMULANT LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ALVIMOPAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALDEMEDINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ENEMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 51. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 52. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 53. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 54. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 55. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 56. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 57. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 58. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 59. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 60. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 61. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 62. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 64. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 65. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 66. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 100. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 101. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 102. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 103. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 104. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 105. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 106. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 107. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 108. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 109. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 110. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 111. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 112. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 113. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 114. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 115. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 124. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 125. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 126. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 127. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 128. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 129. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 130. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 131. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 132. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 133. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 134. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 135. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 136. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 137. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 138. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 139. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 148. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 149. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 156. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 157. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 164. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 165. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 166. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 167. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 168. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 169. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 170. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 171. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 180. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 181. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 182. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 183. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 184. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 185. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 186. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 187. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 188. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 189. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 190. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 191. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 192. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 193. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 194. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 195. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 196. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 197. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 212. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 213. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 214. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 215. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 216. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 217. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 218. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 219. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 220. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 221. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 222. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 223. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 224. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 225. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 226. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 227. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 228. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 229. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 236. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 237. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 238. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 239. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 240. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 241. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 242. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 243. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 244. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 245. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 246. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 247. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 248. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 249. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 250. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 251. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 252. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 260. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 269. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 270. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 271. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 272. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 273. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 274. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 275. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 276. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 277. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 278. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 279. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 280. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 281. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 282. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 283. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 284. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 285. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 286. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 287. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 288. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 289. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 290. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 291. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 292. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 293. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 294. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 295. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 296. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 301. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 302. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 309. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 310. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 311. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 313. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA OPIOID INDUCED CONSTIPATION MARKET S

Companies Mentioned

The companies profiled in this Opioid Induced Constipation market report include:
  • AstraZeneca plc
  • Shionogi & Co., Ltd.
  • H. Lundbeck A/S
  • Bausch Health Companies Inc.
  • Mundipharma International Limited
  • Merck & Co., Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages186
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 75.03 Million
Forecasted Market Value ( USD ) by 2030 $ 103.86 Million
Compound Annual Growth Rate6.7%
Regions CoveredGlobal
No. of Companies Mentioned7

Related Topics

Related Reports

Opioid-Induced Constipation Treatment Market Report 2025 - Product Image

Opioid-Induced Constipation Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Opioid-Induced Constipation - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Opioid-Induced Constipation - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Opioid-Induced Constipation - Pipeline Insight, 2025 - Product Image

Opioid-Induced Constipation - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Opioids Market by Opioid Types, Mode of Administration, Application, End-User - Global Forecast to 2030 - Product Image

Opioids Market by Opioid Types, Mode of Administration, Application, End-User - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
Opioid Use Disorder Market Size, Share & Trends Analysis Report By Drug, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Opioid Use Disorder Market Size, Share & Trends Analysis Report By Drug, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.